Immunotherapy for obesity

Tatsuhiko Azegami, Hiroshi Itoh

Research output: Chapter in Book/Report/Conference proceedingChapter


Obesity prevalence continues to increase in both adults and children worldwide and greatly contributes to increased morbidity and mortality. Although there are some anti-obesity drugs globally available for clinical use, their inadequate effectiveness coupled with safety concerns sometimes discourage the widespread use of anti-obesity medication. Because of its prolonged therapeutic effect and low frequency of administration, a therapeutic vaccine may be an attractive strategy for the prevention and treatment of obesity. Over the last two decades, several attempts have been made to develop vaccines for the control of obesity. Animal studies have shown that vaccines targeting ghrelin, glucose-dependent insulinotropic polypeptide, adipocytes, somatostatin, and adenovirus 36 successfully led to a reduction in weight gain without serious adverse effects. This chapter provides an overview of recent progress toward a therapeutic vaccine against obesity.

Original languageEnglish
Title of host publicationTherapeutic Vaccines as Novel Immunotherapy
Subtitle of host publicationBiological and Clinical Concepts
PublisherSpringer Singapore
Number of pages12
ISBN (Electronic)9789813296282
ISBN (Print)9789813296275
Publication statusPublished - 2020 Jan 1


  • Adenovirus 36
  • Adipocyte
  • Ghrelin
  • Glucose-dependent insulinotropic polypeptide
  • Obesity
  • Somatostatin

ASJC Scopus subject areas

  • General Immunology and Microbiology
  • General Pharmacology, Toxicology and Pharmaceutics
  • General Medicine


Dive into the research topics of 'Immunotherapy for obesity'. Together they form a unique fingerprint.

Cite this